Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens
This study shows that bsAbs that bind carbamylated proteins and FH or C4BP can specifically recruit the endogenous complement regulatory proteins from plasma to achieve selective local targeted complement inhibition, providing a new therapeutic approach for the local treatment of autoimmune diseases.
Authors
- Sander W. Tas (ORCID: https://orcid.org/0000-0002-8940-1788)
- Paul W.H.I. Parren (ORCID: https://orcid.org/0000-0002-4365-3859)
- Elena Domínguez‐Vega (ORCID: https://orcid.org/0000-0002-6394-0783)
- René E. M. Toes (ORCID: https://orcid.org/0000-0002-9618-6414)
- Rick J. Groenland
- Leendert A. Trouw (ORCID: https://orcid.org/0000-0001-5186-2290)
- Christoph Gstöttner (ORCID: https://orcid.org/0000-0003-4033-4024)
- Stef van der Meulen (ORCID: https://orcid.org/0000-0001-6496-603X)
- Jan Piet van Hamburg (ORCID: https://orcid.org/0000-0002-6760-4648)
- Hanneke Kapsenberg
- Sandrine Nugteren
- Haiyu Wang (ORCID: https://orcid.org/0000-0002-6712-3078)
Institutions
- Leiden University Medical Center (NL)
- Netherlands Metabolomics Centre (NL)
- Amsterdam University Medical Centers (NL)
- University of Amsterdam (NL)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2025-07-19
- DOI
- https://doi.org/10.1016/j.ard.2025.06.2130
- Citations
- 5
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 6.80
Funders
- Universiteit Leiden
- China Scholarship Council